VIA
CRSP icon

Vident Investment Advisory’s CRISPR Therapeutics CRSP Stock Holding History

Vident Investment Advisory’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-8,746
Closed -$491K – 237
2023
Q2 		$491K Sell
8,746
-15,207
-63% -$863K 0.02% 705
2023
Q1 		$1.08M Buy
23,953
+2,582
+12% +$125K 0.04% 502
2022
Q4 		$869K Buy
21,371
+6,182
+41% +$328K 0.03% 524
2022
Q3 		$763K Buy
15,189
+2,495
+20% +$181K 0.02% 665
2022
Q2 		$769K Sell
12,694
-4,162
-25% -$245K 0.02% 713
2022
Q1 		$1.06M Buy
16,856
+2,122
+14% +$133K 0.03% 677
2021
Q4 		$1.12M Buy
14,734
+1,880
+15% +$164K 0.03% 664
2021
Q3 		$1.44M Sell
12,854
-1,384
-10% -$174K 0.04% 561
2021
Q2 		$2.31M Buy
14,238
+2,544
+22% +$309K 0.07% 345
2021
Q1 		$1.43M Sell
11,694
-32
-0.3% -$4.83K 0.05% 508
2020
Q4 		$1.79M Sell
11,726
-10,377
-47% -$1.23M 0.07% 328
2020
Q3 		$1.85M Sell
22,103
-819
-4% -$72.6K 0.09% 243
2020
Q2 		$1.68M Sell
22,922
-67
-0.3% -$3.92K 0.09% 250
2020
Q1 		$975K Sell
22,989
-567
-2% -$29.3K 0.06% 404
2019
Q4 		$1.44M Sell
23,556
-8,365
-26% -$457K 0.09% 341
2019
Q3 		$1.31M Sell
31,921
-912
-3% -$43.6K 0.11% 135
2019
Q2 		$1.55M Buy
+32,833
New +$1.31M 0.12% 116

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vident Investment Advisory's CRSP Position: Q3 2023 in Review

Vident Investment Advisory sold out of CRISPR Therapeutics (CRSP) in Q3 2023, closing a stake of 8,746 shares — an estimated $491K sold.

Vident Investment Advisory first reported a position in CRSP in Q2 2019 and held it in 17 quarters. The position peaked at $2.31M in Q2 2021. 406 funds tracked by Wall St. Rank hold CRSP as of Q3 2023.

  • Vident Investment Advisory reported no remaining CRISPR Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Vident Investment Advisory sold 8,746 CRISPR Therapeutics shares in Q3 2023, an estimated $491K.
  • Vident Investment Advisory first reported a position in CRISPR Therapeutics in Q2 2019 and held it in 17 quarters.
  • Vident Investment Advisory's CRISPR Therapeutics position peaked at $2.31M in Q2 2021.
  • 406 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2023.

Based on Vident Investment Advisory's 13F filing for Q3 2023.